Bayer to license Cedilla’s selective inhibitors in precision oncology
German biopharmaceutical company Bayer has signed an exclusive license agreement with Cedilla Therapeutics, a US-based biotechnology company, for its precision oncology candidates. Under the terms of the agreement,